Axonics (AXNX) stock price, revenue, and financials

Axonics market cap is $2.4 b, and annual revenue was $111.54 m in FY 2020

$2.4 B

AXNX Mkt cap, 27-May-2022

$34.4 M

Axonics Revenue Q1, 2021
Axonics Gross profit (Q1, 2021)20.4 M
Axonics Gross profit margin (Q1, 2021), %59.3%
Axonics Net income (Q1, 2021)-22.5 M
Axonics EBIT (Q1, 2021)-21.6 M
Axonics Cash, 31-Mar-2021131 M
Axonics EV2.3 B
Get notified regarding key financial metrics and revenue changes at AxonicsLearn more
Banner background

Axonics Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

128.1k707.0k13.8m111.5m

Cost of goods sold

117.9k356.0k6.5m44.4m

Gross profit

10.2k351.0k7.3m67.1m

Gross profit Margin, %

8%50%53%60%

Sales and marketing expense

516.1k1.0m3.7m48.7m66.1m

R&D expense

12.5m12.3m19.4m20.2m29.2m

General and administrative expense

4.5m4.8m9.4m19.1m25.6m

Operating expense total

17.5m18.2m32.5m87.9m120.9m

EBIT

(17.5m)(18.2m)(32.1m)(80.6m)(53.8m)

EBIT margin, %

(14186%)(4546%)(584%)(48%)

Interest income

84.0k200.6k

Investment income

998.0k3.0m761.0k

Pre tax profit

(32.5m)(79.9m)(54.9m)

Income tax expense

1.0k1.0k1.0k

Net Income

(17.4m)(18.1m)(32.5m)(79.9m)(54.9m)

Axonics Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

8.2m24.4m98.3m171.1m241.2m

Accounts Receivable

427.0k7.9m18.3m

Prepaid Expenses

520.2k979.7k3.7m4.5m5.4m

Inventories

1.5m3.7m15.7m63.1m

Current Assets

8.7m26.9m165.3m211.7m327.9m

PP&E

1.2m1.5m2.8m3.0m6.3m

Total Assets

10.9m29.4m171.9m219.8m342.2m

Accounts Payable

630.3k1.6m3.4m5.9m10.7m

Short-term debt

768.0k602.0k22.4m

Current Liabilities

1.5m2.4m5.9m12.0m45.7m

Long-term debt

301.5k135.0k22.7m24.8m30.3m

Total Debt

301.5k135.0k22.7m25.4m52.7m

Total Liabilities

1.8m2.5m28.6m36.8m54.8m

Common Stock

233.0278.03.0k3.0k4.0k

Preferred Stock

58.5m93.3m

Additional Paid-in Capital

1.8m2.9m243.3m363.0m522.3m

Retained Earnings

(49.1m)(67.2m)(99.6m)(179.6m)(234.5m)

Total Equity

9.4m26.9m143.3m183.0m287.4m

Debt to Equity Ratio

0 x0 x0.2 x0.1 x0.2 x

Debt to Assets Ratio

0 x0 x0.1 x0.1 x0.2 x

Financial Leverage

1.2 x1.1 x1.2 x1.2 x1.2 x

Quarterly

USDQ2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

24.7m20.1m89.3m82.7m76.2m159.8m287.7m269.3m131.0m

Accounts Receivable

13.6k219.0k804.0k1.3m954.0k20.8m14.1m17.7m21.5m

Prepaid Expenses

1.6m1.8m2.8m3.1m2.6m4.2m3.6m3.2m4.7m

Inventories

1.9m2.1m5.1m8.0m12.7m19.2m30.1m44.3m71.2m

Current Assets

43.4m35.3m152.8m138.0m117.8m204.1m335.5m334.5m228.4m

PP&E

1.5m2.8m2.9m3.0m3.0m5.4m5.6m5.8m6.0m

Goodwill

87.4m

Total Assets

45.8m42.3m159.4m146.5m126.0m217.4m348.7m347.7m445.0m

Accounts Payable

2.1m2.0m2.1m3.2m4.2m7.4m10.7m9.4m11.4m

Short-term debt

800.0k2.2m4.5m7.0m5.8m10.9m15.9m1.4m

Current Liabilities

5.0m5.5m6.7m11.3m15.5m19.8m30.8m38.8m24.0m

Long-term debt

9.0m12.5m21.4m20.7m18.3m25.1m20.0m15.0m84.0m

Total Debt

9.0m13.3m23.1m24.6m24.7m30.9m30.9m30.9m85.4m

Total Liabilities

14.0m18.0m28.1m32.0m33.9m44.9m50.8m53.8m114.8m

Common Stock

283.03.0k3.0k3.0k3.0k4.0k4.0k4.0k

Preferred Stock

113.2m

Additional Paid-in Capital

3.2m3.3m244.5m246.7m249.6m367.3m512.6m517.7m589.8m

Retained Earnings

(82.4m)(90.0m)(112.8m)(131.8m)(156.8m)(194.2m)(214.0m)(223.2m)(257.0m)

Total Equity

31.8m42.3m131.3m114.4m92.2m172.5m297.9m293.9m330.2m

Debt to Equity Ratio

0.3 x0.2 x0.2 x0.3 x0.2 x0.1 x0.1 x

Debt to Assets Ratio

0.2 x0.1 x0.2 x0.2 x0.1 x0.1 x0.1 x

Financial Leverage

1.4 x1 x1.2 x1.3 x1.4 x1.3 x1.2 x1.2 x1.3 x

Axonics Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(17.4m)(18.1m)(32.5m)(79.9m)(54.9m)

Depreciation and Amortization

625.1k725.4k946.0k1.2m1.7m

Accounts Receivable

(427.0k)(7.5m)(10.8m)

Inventories

(1.5m)(2.3m)(12.0m)(47.4m)

Accounts Payable

(1.0m)985.4k1.8m2.4m4.8m

Cash From Operating Activities

(17.3m)(18.2m)(31.4m)(83.5m)(83.7m)

Purchases of PP&E

(292.1k)(1.0m)(1.2m)(1.3m)(2.9m)

Cash From Investing Activities

(292.1k)(1.0m)(60.0m)45.3m9.7m

Cash From Financing Activities

1.6m34.8m165.3m111.0m144.2m

Net Change in Cash

(16.0m)16.2m73.9m72.8m70.1m

Interest Paid

751.0k1.4m1.1m

Income Taxes Paid

800.0890.01.0k1.0k1.0k

Quarterly

USDQ2, 2017Q3, 2017Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(8.6m)(13.1m)(15.3m)(22.8m)(13.1m)(32.2m)(57.2m)(14.6m)(34.4m)(43.6m)(22.5m)

Depreciation and Amortization

334.7k514.0k427.6k663.0k276.0k570.0k880.0k380.0k806.0k1.3m1.1m

Accounts Receivable

(13.6k)(377.0k)(859.0k)(527.0k)(13.4m)(6.7m)(10.2m)(1.5m)

Inventories

(519.2k)(813.0k)(371.9k)(607.0k)(1.4m)(4.3m)(9.0m)(3.6m)(14.4m)(28.6m)(7.2m)

Accounts Payable

453.5k498.0k471.7k367.0k(1.3m)(881.0k)796.0k1.6m4.8m3.5m914.0k

Cash From Operating Activities

(8.4m)(12.8m)(14.0m)(22.1m)(13.1m)(31.4m)(55.3m)(23.3m)(36.3m)(55.4m)(25.6m)

Purchases of PP&E

(250.0k)(492.0k)(298.7k)(1.0m)(350.0k)(729.0k)(962.0k)(714.0k)(1.3m)(1.9m)(123.0k)

Cash From Investing Activities

(250.0k)(492.0k)(15.5m)(11.9m)4.0m15.5m32.9m11.9m11.3m10.7m(140.9m)

Long-term Borrowings

(21.5m)

Cash From Financing Activities

19.9m34.8m29.8m29.8m44.0k352.0k463.0k344.0k141.8m143.1m56.2m

Net Change in Cash

11.3m22.1m331.7k(4.2m)(9.0m)(15.6m)(22.1m)(11.3m)116.6m98.2m(110.2m)

Interest Paid

204.6k393.0k360.0k730.0k1.1m329.0k593.0k849.0k170.0k

Income Taxes Paid

800.0800.0800.01.0k1.0k1.0k

Axonics Ratios

USDFY, 2016

Financial Leverage

1.2 x

Axonics Operating Metrics

Q3, 2018

Patent Applications

76

Patents Issued

37

Patients Reached

180

Axonics Employee Rating

425 votes
Culture & Values
4.7
Work/Life Balance
4.7
Senior Management
5
Salary & Benefits
5
Career Opportunities
4.9
Source